Straits Times Index
3,322.62 +14.72 (+0.45%) S&P 500
5,264.20 -42.81 (-0.81%) Dow
39,040.49 -630.55 (-1.59%) Nasdaq
16,720.30 -81.25 (-0.48%) Bitcoin USD
67,303.11 -2,341.80 (-3.36%) CMC Crypto 200
1,465.46 -37.21 (-2.48%)
MDT Jun 2024 77.500 call
- Benzinga
Medtronic's Q4 Earnings: Medical Device Giant Clocks Strong Sales From Neurology Devices, Hikes Dividend
Medtronic Plc (NYSE:MDT) reported fourth-quarter 2024 sales of $8.59 billion, beating the consensus of $8.44 billion. Revenue increased 0.5%, as reported, and 5.4% organic. The company’s organic revenue results reflect broad-based growth across the company, with mid-single-digit or higher organic revenue growth in all four segments. The medical device maker reported adjusted EPS of $1.46, beating the consensus of $1.45. Related: Medtronic’s Latest Generation Of Transcatheter Aortic Valve Replace
- Zacks
Medtronic (MDT) Q4 Earnings Beat Estimates, Margins Down
Growth across Cranial & Spinal Technologies, Diabetes, Cardiac Pacing and Surgical businesses contributes to Medtronic's (MDT) Q4 revenues.
- Zacks
Compared to Estimates, Medtronic (MDT) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Medtronic (MDT) give a sense of how the business performed in the quarter ended April 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
